gsk glp-1 promotes osteogenic differentiation of human ADSCs via the Wnt/GSK-3β/β-catenin pathway Frontiers | Neuroprotective Mechanisms of

Blue Cross Blue Shield of Michigan ended its coverage for Wegovy, Saxenda and Zepound to treat weight loss for many of its plans this year, requiring new prior authorization for the drugs for some obese adult patients

Both medications have shown potential in supporting cardiovascular health

The plausible timeline, reconstructed from Lilly's disclosed trial schedule and standard regulatory review windows, looks roughly like this: Q2-Q3 2026: TRIUMPH-1 and TRIUMPH-2 readouts

Be honest about finances: If you have insurance constraints, or if youre paying out of pocket, your provider can better navigate possible manufacturer coupons or alternative medications

If state Medicaid programs estimate the costs from expanded use will outweigh the savings, initial state Medicaid participation may be limited, especially given recent state budget challenges and federal funding cuts

They found that bariatric surgery was less costly and provided more QALYs than semaglutide